Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

12-09-2022 | ESMO 2022 | Conference coverage | Video

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm (4:42).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

09-09-2022 | ESMO 2022 | Conference coverage | News

Sacituzumab govitecan boosts HR+, HER2– advanced breast cancer OS

05-06-2022 | ASCO 2022 | Conference coverage | News

TROPiCS-02 supports sacituzumab govitecan for HR+, HER2– advanced breast cancer

06-06-2022 | ASCO 2022 | Conference coverage | News

DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer
Image Credits